Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:
Introduction (00:00)
Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
Strategies to Prevent and Manage Hyperglycemia (27:02)
Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
Mitigation and Management of Gastrointestinal Adverse Events (51:05)
Management of Dermatologic Adverse Events (59:58)
Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av,
eller tillsammans med, Poddtoppen.